Synapse - Andrew Plodkowski

Results (19)

The effects of neoadjuvant chemotherapy and intervalde bulking surgery on body composition in patients with ovarian cancer

Journal Article

Vitarello, J.; Goncalves, M. D.; Zhou, Q. C.; Iasonos, A.; Halpenny, D. F.; Plodkowski, A.; Schwitzer, E.; Mueller, J. J.; Zivanovic, O.; Jones, L. W.; more...
JCSM Clinical Reports (2021)

Fulltext@MSK | Save

Response to immune checkpoint inhibition as monotherapy or in combination with chemotherapy in metastatic ROS1-rearranged lung cancers

Journal Article

Choudhury, N. J.; Schneider, J. L.; Patil, T.; Zhu, V. W.; Goldman, D. A.; Yang, S. R.; Falcon, C. J.; Do, A.; Nie, Y.; Plodkowski, A. J.; more...
JTO Clinical and Research Reports (2021)

Fulltext@MSK | Save

Association of a very high tumor mutational load with increased CD8+ and PD-1+ T-cell infiltration and improved clinical outcomes to PD-(L)1 blockade across different PD-L1 expression levels in non-small cell lung cancer

Meeting Abstract

Ricciuti, B.; Arbour, K. C.; Alessi, J. V. M.; Mahadevan, N.; Lindsay, J.; Sinha, R.; Vokes, N. I.; Recondo, G.; Lamberti, G.; Rizvi, H.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Determination of clinical benefit among patients with radiological stable disease to immune checkpoint inhibitors

Meeting Abstract

Luo, J.; Wu, S.; Rizvi, H.; Zhang, Q.; Egger, J. V.; Osorio, J. C.; Schoenfeld, A. J.; Plodkowski, A. J.; Ginsberg, M. S.; Gupta, A. K.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Response to immune checkpoint inhibition as monotherapy or in combination with chemotherapy in metastatic ROS1-rearranged lung cancers

Meeting Abstract

Choudhury, N. J.; Schneider, J. L.; Patil, T.; Zhu, V. W.; Goldman, D. A.; Yang, S. R.; Falcon, C.; Do, A.; Nie, Y.; Plodkowski, A. J.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer

Journal Article

Castellanos, S. H.; Pagano, A.; Plodkowski, A. J.; Girshman, J.; Hellmann, M. D.; Rizvi, H.; Flynn, J.; Zheng, J.; Capanu, M.; Halpenny, D. F.; more...
Lung Cancer (2021)

Fulltext@MSK | Save

Immunotherapy-mediated thyroid dysfunction: Genetic risk and impact on outcomes with PD-1 blockade in non-small cell lung cancer

Journal Article

Luo, J.; Martucci, V. L.; Quandt, Z.; Groha, S.; Murray, M. H.; Lovly, C. M.; Rizvi, H.; Egger, J. V.; Plodkowski, A. J.; Abu-Akeel, M.; more...
Clinical Cancer Research (2021)

Fulltext@MSK | Save

A very high tumor mutational burden (TMB) is associated with improved efficacy of PD-(L)1 inhibition across different PD-L1 expression subgroups and a distinct immunophenotype in NSCLC